Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioengineered Penile Tissue Constructs for Damaged Penile Corpora
NCT03463239Phase 1Not yet recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2027
- Primary completion
- Dec 2030
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous tissue engineered corpora in penile deformity, sponsored by Wake Forest University Health Sciences. Primary endpoint: Treatment-related adverse events at 36 months. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
autologous tissue engineered corpora
03
Conditions
penile deformity
Beyond the preview
Go deeper on NCT03463239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03463239.